PenTAG Health Technology Assessment
*****PenTAG is recruiting*****
There is an opportunity for a health economic modeller to join our group. Deadline for applications: 8 May 2017. Please find details here:
PenTAG is the team of researchers within ESMI that specialise in conducting health technology assessment for national policy makers in England and Wales.
PenTAG is one of several university-based research groups in the UK contracted to produce high quality systematic reviews and economic analyses of health technologies for NICE, the UK National Screening Committee and the NIHR HTA programme.
Our work supporting NICE falls under three categories:
- Multiple Technology Appraisals (MTAs) – We produce systematic reviews of the existing literature on clinical and cost-effectiveness, critique analyses from manufacturers and develop a new economic analysis to support decisions when multiple technologies are being appraised. These projects lead to published monographs in the journal Health Technology Assessment and can also lead to journal articles. Past MTA projects
- Single Technology Appraisals (STAs) – We perform a rapid review of the evidence supporting a new drug or medical device supplied to NICE by the manufacturer. This helps to ensure that all relevant clinical effectiveness evidence is included, that cost-effectiveness analyses are robust, and that Appraisal Committees are confident that methods have been independently reviewed. Past STA projects
- Diagnostics Assessment (DA) – A relatively new process, similar to that for MTAs, for which we undertake an assessment of the diagnostic test accuracy, clinical outcomes and cost-effectiveness of a diagnostic technology. These projects lead to published monographs in the journal Health Technology Assessment and can also lead to journal articles.
In addition staff members actively seek additional research funding in areas of interest to them, often stemming from work commissioned by NICE or NIHR.
Our research staff come from a variety of backgrounds, including specialists in systematic review methods, health economics, information science, computer science and statistics. We are additionally able to draw on substantial expertise from other groups in the Institute for Health Research, such as the health statistics and health economics groups.
Treatment Switching Workshop
PenTAG hosted an interesting workshop titled “Methods for adjusting for treatment switching in randomised trials” at our offices at St Luke’s campus, Exeter, on 20th and 21st April.
There were 36 attendees: mostly from the University of Exeter Medical School, NICE and from all the other eight academic centres across the UK that perform health technology assessments at the national level. The tutors were Dr Ian White (MRC Biostatistics Unit, Cambridge) and Dr Nick Latimer (HEDS, Sheffield).
The workshop was worthwhile and topical because the use of sophisticated statistical methods to adjust for treatment switching in RCTs is increasing, and because these adjustments can change the estimated cost-effectiveness of drugs substantially.
Release of our economic models
We are happy to consider releasing copies of our economic models of health technologies to not-for-profit organisations within the UK or overseas, such as other universities or government agencies. Please contact Martin Hoyle.
Workstream Lead: Prof Martin Hoyle
|NICE STA||Lenalidomide for multiple myeloma post bortezomib (Celgene)||N Huxley, L Long, M Hoyle, C Rudin, S Briscoe|
|NICE rapid review of drugs on CDF list||Bosutinib (Pfizer) CDF rapid review||T Snowsill, L Long, C Rudin|
|NICE DAR||Genetic testing for Lynch syndrome in people with colorectal cancer||H Coehlo, T Jones-Hughes, C Hyde, T Snowsill, N Huxley, C Cooper, S Briscoe|
|NICE MTA||Everolimus, lanreotide, lutetium-177 DOTATATE and sunitinib for treating unresectable or metastatic neuroendocrine tumours with disease progression||M Haasova, J Varley-Campbell, I Tikhonova, M Hoyle, R Mujica-Mota, E Griffin, S Lucherini, C Cooper|
|NICE MTA||Cetuximab (review of TA176) and panitumumab (partial review of TA240) for the first line treatment of metastatic colorectal cancer||N Huxley, L Crathorne, J Varley-Campbell, I Tikhonova, T Snowsill, S Briscoe, J Peters, M Napier, M Bond, M Hoyle|
|Royal Devon and Exeter NHS Foundation Trust||Pain relief for venous cannulation of adults in routine treatment settings: a systematic review. Registered on PROSPERO||M Bond, H Coelho, C Cooper, L Crathorne, M Haasova, C Hyde|
|Health Innovation Challenge Fund (funded by Wellcome Trust and Department of Health)||UNITED study: Using pharmacogenetics to improve treatment in early-onset diabetes. Clinical study and economic evaluation.
||J Peters, R Anderson, C Hyde|
|NIHR RfPB||Deriving evidence-based clinical criteria to aid classification of diabetes. A systematic review and validation study.
||BM Shields, JL Peters, C Cooper, RJ Powell, BA Knight, C Hyde, AT Hattersley, J Lowe, E Youngman|
|NIHR HTA||Effectiveness and cost-effectiveness of conservative interventions for tendinopathy: an overview of systematic reviews of clinical effectiveness and systematic review of economic evaluations (monograph in press)||L Long, S Briscoe, C Cooper, C Hyde, L Crathorne|
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
|R Mujica Mota, J Varley-Campbell, I Tikhonova, C Cooper, M Hoyle, C Rudin, T Snowsill|
|NIHR HTA||Cost-effectiveness of screening for permanent hearing loss in children at school entry
||H Fortnum, C Benton, C Hyde, J Moody, R Taylor, O Ukoumunne, A Allardice, M Ozolins, S Catterick, E Youngman, N Huxley, T Snowsill|
|NIHR CLAHRC South West Peninsula (PenCLAHRC) and NIHR||Psychological consequences of false-positive screening mammograms||M Bond, C Hyde|
|NICE MTA||Erythropoiesis stimulating agents (epoetin and darbepoetin) for cancer-treatment induced anaemia||L Crathorne, N Huxley, M Haasova, T Snowsill, T Jones‑Hughes, M Hoyle, S Briscoe, H Coelho, L Long, A Medina‑Lara, R Mujica‑Mota, C Hyde|
|NICE MTA||Immunosuppressive therapy for renal transplantation in adolescents and children (including a review of existing guidance 99)||R Anderson, M Bond, C Cooper, L Crathorne, M Haasova, R Mujica‑Mota, T Snowsill, N Huxley||Monograph|
|NICE MTA||Immunosuppressive therapy for renal transplantation in adults (including a review of existing guidance 85)||R Anderson, M Bond, H Coelho, C Cooper, M Haasova, T Jones‑Hughes, J Varley-Campbell, R Mujica‑Mota, T Snowsill, M Allwood, N Huxley||Monograph|
|NICE DA||Sysmex RD-100i OSNA system and Metasin for intraoperative detection of sentinel lymph node metastases in breast cancer (monograph in press)||N Huxley, T Jones‑Hughes, H Coelho, T Snowsill, C Cooper, K Cooper, Y Meng, C Hyde, R Mujica‑Mota||Monograph|
|NIHR HTA||Diagnostic strategies for identifying Lynch syndrome in early-onset colorectal cancer patients (monograph in press)||T Snowsill, N Huxley, M Hoyle, T Jones‑Hughes, H Coelho, C Cooper, I Frayling, C Hyde|
|NICE MTA||Bevacizumab, Cetuximab, and Panitumumab for in colorectal cancer (metastatic) after failure of 1st line chemotherapy||M Hoyle, L Crathorne, J Peters, T Jones‑Hughes, C Cooper, M Napier, P Tappenden, C Hyde|
|NIHR HTA||Psychological consequences of false positive mammograms||M Bond, T Pavey, K Welch, C Cooper, R Garside, S Dean, C Hyde||Monograph
Journal article (Editor's choice, Evidence Based Medicine)
|NICE MTA||Dasatinib and Nilotinib for the 1st line treatment of chronic phase CML||T Pavey, M Hoyle, O Ciani, L Crathorne, T Jones‑Hughes, C Cooper, L Osipenko, M Venkatachalam, C Rudin, O Ukoumunne, R Garside, R Anderson||Monograph|
|NICE MTA||Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant or imatinib-intolerant CML||G Rogers, M Hoyle, J Thompson Coon, T Moxham, Z Liu, M Pitt, K Stein||Monograph
Journal article (Value in Health)
|NICE MTA||Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease||M Bond, G Rogers, J Peters, R Anderson, M Hoyle, A Miners, T Moxham, S Davis, P Thokala, A Wailoo, M Jeffreys, C Hyde||Monograph
Journal article #1 (International Journal of Technology Assessment in Health Care)
Journal article #2 (Age and Ageing)
|NIHR HTA||Computerised decision support systems in Order Communication for diagnostic, screening or monitoring test ordering: systematic reviews of the effects and cost-effectiveness of systems||C Main, T Moxham, JC Wyatt, J Kay, R Anderson, K Stein||Monograph|
|NICE MTA||Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: A systematic review and economic model||J Thompson Coon, M Hoyle, C Green, Z Liu, K Welch, T Moxham, K Stein||Monograph
Journal article #1 (Value in Health)
Journal article #2 (Value in Health)
Journal article #3 (British Journal of Cancer)
|NIHR HTA||Weight management schemes for the under fives||M Bond, K Wyatt, J Lloyd, K Welch, R Taylor||Monograph|
|NICE MTA||Cochlear implants for severe to profound deafness in children and adults||M Bond, S Mealing, R Anderson, J Elston, G Weiner, R Taylor, M Hoyle, Z Liu, A Price, K Stein||Monograph
Journal article #1 (Clinical Otolaryngology)
Journal article #2 (updated searches; Clinical Otolaryngology)
|NICE MTA||Methods of storing donated kidneys from deceased donors||M Bond, M Pitt, J Akoh, T Moxham, M Hoyle, R Anderson||Monograph|
|NIHR HTA||Systematic review of the harmful health effects of taking ecstasy (MDMA) for recreational purposes||G Rogers, J Elston, R Garside, C Roome, R Taylor, P Younger, A Zawada, M Somerville||Monograph|
|NIHR HTA||C Main, Z Liu, K Welch, G Weiner, SQ Jones, K Stein|
Further past projects can be found here.
- Rob Anderson
- Simon Briscoe
- Helen Coelho
- Chris Cooper (Deputy Director)
- James Dunham
- Ed Griffin
- Martin Hoyle (Director)
- Chris Hyde
- Tracey Jones‑Hughes
- Linda Long
- Jenny Lowe
- Ruben Mujica‑Mota
- Jaime Peters
- Sophie Robinson
- Tristan Snowsill (Deputy Director)
- Irina Tikhonova
- Jo Varley-Campbell
- Sue Whiffin
- Huiqin Yang (Deputy Director)